(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCQB Venture Market.)

Our mission is to provide novel diagnostic tools that optimize outcomes and quality of life for all patients along the continuum of oncology care, from cancer screening through treatment and monitoring. 

We have one wholly owned subsidiary: StemPrintER Sciences Limited, a private company incorporated in England and Wales with limited liability under the Companies Act

We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the more than 18 million people worldwide who are diagnosed with cancer each year. Our plan is to develop and commercialize a suite of novel genomic tests that support decision making along the entire continuum of oncology care.

Our focus will be the commercialization of our proprietary genomic test, StemPrintER, for patients with early stage breast cancer, and we estimate this market opportunity represents more than $1.3 billion in annual revenue.

Our primary product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (“DR”) in luminal (ER+/HER2-negative) breast cancer patients. The assay was developed to measure the “stemness” of tumors, or how much a tumor behaves like stem cells which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multi-disciplinary care team. StemPrintER has been validated in several clinical cohorts and studies , the largest of which are a consecutive series of approximately 2,400 patients from the European Institute of Oncology (“IEO”) and approximately 800 patients from the TransATAC study. In the IEO cohort, StemPrintER High Risk patients (“SPRS High”) were 1.85 times more likely to have a distant recurrence compared to Low Risk (“SPRS Low”) patients (Figure 1) and in the TransATAC cohort, SPRS High patients were 4.27 times more likely to experience a distant recurrence compared to SPRS Low Risk patients (Figure 2). Together, these data confirm that StemPrintER is highly prognostic for outcomes in patients with breast cancer and indicate the potential utility of the test in the oncology clinic.

**Note: Revenue and net loss figures are for the nine months that ended Sept. 30, 2022.

(Note: AccuStem Sciences Inc. filed an S-1/A dated Jan. 19, 2023, in which it disclosed the terms for its public offering in connection with its NASDAQ uplisting from the OTCQB Venture Market: 1.48 million shares (1,478,495 shares) at $7.44, the last reported sale price of AccuStem’s stock on the OTCQB Venture Market, as adjusted for a 1-for-6 reverse stock split, to raise $11.0 million. AccuStem Sciences Inc. filed its S-1 on Nov. 17, 2022; it submitted confidential IPO documents to the SEC on July 29, 2022.)